Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

EHA 2015

11–14 June 2015 | Reed Messe, Vienna, Austria

EHA 2015

11–14 June 2015 | Reed Messe, Vienna, Austria
Novel combination therapies for the treatment of non-Hodgkin lymphoma 2:15
Novel combination therapies for the treatment of non-Hodgkin lymphoma
Andrew Davies • 11 Jun 2015
ELOQUENT-2 trial: Elotuzumab for relapsed or refractory multiple myeloma 2:04
ELOQUENT-2 trial: Elotuzumab for relapsed or refractory multiple myeloma
Jesús San Miguel • 11 Jun 2015
Final analysis of the phase 4 EXELS trial in high-risk patients with essential thrombocythemia 3:40
Final analysis of the phase 4 EXELS trial in high-risk patients with essential thrombocythemia
Claire Harrison • 12 Jun 2015
Improving outcomes in elderly patients with cancer 2:33
Improving outcomes in elderly patients with cancer
Matti Aapro • 12 Jun 2015
Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL 1:59
Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL
Dieter Hoelzer • 12 Jun 2015
An update on the phase 3 MDS-005 trial 6:02
An update on the phase 3 MDS-005 trial
Valeria Santini • 11 Jun 2015
Novel agents for MDS on the basis of understanding disease biology 3:44
Novel agents for MDS on the basis of understanding disease biology
Valeria Santini • 12 Jun 2015
Outlook for the management of chronic myeloid leukemia 1:38
Outlook for the management of chronic myeloid leukemia
Stephen O’Brien • 12 Jun 2015
Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia 4:33
Optimizing discontinuation of tyrosine kinase inhibitor treatment for chronic myeloid leukemia
Gianantonio Rosti • 12 Jun 2015
Engaging patients in clinical research 2:03
Engaging patients in clinical research
Stephen O’Brien • 12 Jun 2015
Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia 3:12
Second-generation tyrosine kinase inhibitors for chronic myeloid leukemia
Giuseppe Saglio • 12 Jun 2015
Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia 2:03
Update on the efficacy and safety of tyrosine kinase inhibitors for chronic myeloid leukemia
Giuseppe Saglio • 12 Jun 2015
The Trials Acceleration Programme by Leukaemia & Lymphoma Research 3:04
The Trials Acceleration Programme by Leukaemia & Lymphoma Research
Charles Craddock • 12 Jun 2015
Adaptive licensing: A new approach for authorizing medicines 0:55
Adaptive licensing: A new approach for authorizing medicines
Stephen O’Brien • 12 Jun 2015
Considerations for drug development in hematological oncology 5:06
Considerations for drug development in hematological oncology
Matti Aapro • 12 Jun 2015

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals